Emanuela Altobelli1, Ruchika Mohan2, Kathleen E Mach2, Mandy Lai Yi Sin2, Victoria Anikst3, Maurizio Buscarini4, Pak Kin Wong5, Vincent Gau6, Niaz Banaei3, Joseph C Liao7. 1. Department of Urology, Stanford University School of Medicine, Stanford, CA, USA; Department of Urology, Campus Biomedico University of Rome, Rome, Italy. 2. Department of Urology, Stanford University School of Medicine, Stanford, CA, USA. 3. Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA. 4. Department of Urology, Campus Biomedico University of Rome, Rome, Italy. 5. Department of Aerospace and Mechanical Engineering, The University of Arizona, Tucson, AZ, USA. 6. GeneFluidics, Irwindale, CA, USA. 7. Department of Urology, Stanford University School of Medicine, Stanford, CA, USA; Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA. Electronic address: jliao@stanford.edu.
Abstract
BACKGROUND: Standard diagnosis of urinary tract infection (UTI) via urine culture for pathogen identification (ID) and antimicrobial susceptibility testing (AST) takes 2-3 d. This delay results in empiric treatment and contributes to the misuse of antibiotics and the rise of resistant pathogens. A rapid diagnostic test for UTI may improve patient care and antibiotic stewardship. OBJECTIVE: To develop and validate an integrated biosensor assay for UTI diagnosis, including pathogen ID and AST, with determination of the minimum inhibitory concentration (MIC) for ciprofloxacin. DESIGN, SETTING, AND PARTICIPANTS: Urine samples positive for Enterobacteriaceae (n=84) or culture-negative (n=23) were obtained from the Stanford Clinical Microbiology Laboratory between November 2013 and September 2014. Each sample was diluted and cultured for 5h with and without ciprofloxacin, followed by quantitative detection of bacterial 16S rRNA using a single electrochemical biosensor array functionalized with a panel of complementary DNA probes. Pathogen ID was determined using universal bacterial, Enterobacteriaceae (EB), and pathogen-specific probes. Phenotypic AST with ciprofloxacin MIC was determined using an EB probe to measure 16S rRNA levels as a function of bacterial growth. MEASUREMENTS: Electrochemical signals for pathogen ID at 6 SD over background were considered positive. An MIC signal of 0.4 log units lower than the no-antibiotic control indicated sensitivity. Results were compared to clinical microbiology reports. RESULTS AND LIMITATIONS: For pathogen ID, the assay had 98.5% sensitivity, 96.6% specificity, 93.0% positive predictive value, and 99.3% negative predictive value. For ciprofloxacin MIC the categorical and essential agreement was 97.6%. Further automation, testing of additional pathogens and antibiotics, and a full prospective study will be necessary for translation to clinical use. CONCLUSIONS: The integrated biosensor platform achieved microbiological results including MIC comparable to standard culture in a significantly shorter assay time. Further assay automation will allow clinical translation for rapid molecular diagnosis of UTI. PATIENT SUMMARY: We have developed and validated a biosensor test for rapid diagnosis of urinary tract infections. Clinical translation of this device has the potential to significantly expedite and improve treatment of urinary tract infections. Published by Elsevier B.V.
BACKGROUND: Standard diagnosis of pan class="Disease">urinary tract infection (UTI) via urine culture for pathogen identification (ID) and antimicrobial susceptibility testing (AST) takes 2-3 d. This delay results in empiric treatment and contributes to the misuse of antibiotics and the rise of resistant pathogens. A rapid diagnostic test for UTI may improve patient care and antibiotic stewardship. OBJECTIVE: To develop and validate an integrated biosensor assay for UTI diagnosis, including pathogen ID and AST, with determination of the minimum inhibitory concentration (MIC) for ciprofloxacin. DESIGN, SETTING, AND PARTICIPANTS: Urine samples positive for Enterobacteriaceae (n=84) or culture-negative (n=23) were obtained from the Stanford Clinical Microbiology Laboratory between November 2013 and September 2014. Each sample was diluted and cultured for 5h with and without ciprofloxacin, followed by quantitative detection of bacterial 16S rRNA using a single electrochemical biosensor array functionalized with a panel of complementary DNA probes. Pathogen ID was determined using universal bacterial, Enterobacteriaceae (EB), and pathogen-specific probes. Phenotypic AST with ciprofloxacin MIC was determined using an EB probe to measure 16S rRNA levels as a function of bacterial growth. MEASUREMENTS: Electrochemical signals for pathogen ID at 6 SD over background were considered positive. An MIC signal of 0.4 log units lower than the no-antibiotic control indicated sensitivity. Results were compared to clinical microbiology reports. RESULTS AND LIMITATIONS: For pathogen ID, the assay had 98.5% sensitivity, 96.6% specificity, 93.0% positive predictive value, and 99.3% negative predictive value. For ciprofloxacin MIC the categorical and essential agreement was 97.6%. Further automation, testing of additional pathogens and antibiotics, and a full prospective study will be necessary for translation to clinical use. CONCLUSIONS: The integrated biosensor platform achieved microbiological results including MIC comparable to standard culture in a significantly shorter assay time. Further assay automation will allow clinical translation for rapid molecular diagnosis of UTI. PATIENT SUMMARY: We have developed and validated a biosensor test for rapid diagnosis of urinary tract infections. Clinical translation of this device has the potential to significantly expedite and improve treatment of urinary tract infections. Published by Elsevier B.V.
Authors: Joseph C Liao; Mitra Mastali; Vincent Gau; Marc A Suchard; Annette K Møller; David A Bruckner; Jane T Babbitt; Yang Li; Jeffrey Gornbein; Elliot M Landaw; Edward R B McCabe; Bernard M Churchill; David A Haake Journal: J Clin Microbiol Date: 2006-02 Impact factor: 5.948
Authors: Joseph C Liao; Mitra Mastali; Yang Li; Vincent Gau; Marc A Suchard; Jane Babbitt; Jeffrey Gornbein; Elliot M Landaw; Edward R B McCabe; Bernard M Churchill; David A Haake Journal: J Mol Diagn Date: 2007-04 Impact factor: 5.568
Authors: Kalpana Gupta; Thomas M Hooton; Kurt G Naber; Björn Wullt; Richard Colgan; Loren G Miller; Gregory J Moran; Lindsay E Nicolle; Raul Raz; Anthony J Schaeffer; David E Soper Journal: Clin Infect Dis Date: 2011-03-01 Impact factor: 9.079
Authors: Mandy L Y Sin; Tingting Liu; Jeffrey D Pyne; Vincent Gau; Joseph C Liao; Pak Kin Wong Journal: Anal Chem Date: 2012-03-06 Impact factor: 6.986
Authors: Susana Campuzano; Filiz Kuralay; M Jesús Lobo-Castañón; Martin Bartošík; Kedar Vyavahare; Emil Paleček; David A Haake; Joseph Wang Journal: Biosens Bioelectron Date: 2011-02-15 Impact factor: 10.618
Authors: George G Zhanel; Tamiko L Hisanaga; Nancy M Laing; Melanie R DeCorby; Kim A Nichol; Barb Weshnoweski; Jack Johnson; Ayman Noreddin; Don E Low; James A Karlowsky; Daryl J Hoban Journal: Int J Antimicrob Agents Date: 2006-05-18 Impact factor: 5.283
Authors: Jian Gao; Hui Li; Peter Torab; Kathleen E Mach; David W Craft; Neal J Thomas; Chris M Puleo; Joseph C Liao; Tza-Huei Wang; Pak Kin Wong Journal: Nanomedicine Date: 2019-02-20 Impact factor: 5.307
Authors: Jian Gao; Lindsie Jeffries; Kathleen E Mach; David W Craft; Neal J Thomas; Vincent Gau; Joseph C Liao; Pak Kin Wong Journal: SLAS Technol Date: 2016-05-25 Impact factor: 3.047